Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

In South Korea, public health authorities have expressed concern about smoking in HIV patients due to the habit’s high societal acceptance.

Contineum Therapeutics has concluded targeted enrolment in a Phase II trial of PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.

MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.